Drugs / VEGFR2 peptide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00677612 | May 2008 → Mar 2009 | colon carcinoma, rectal cancer | Tokyo University | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00677326 | May 2008 → Apr 2009 | breast cancer | Tokyo University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEGFR2 peptide | “On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00677612 ↗1“VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00677326 ↗ |
| Modality | Peptide | “VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00677326 ↗ |
| Route | Subcutaneous | “VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00677326 ↗ |